Bionic Vision Technologies Pty. Ltd.

Based in Australia, Bionic Vision Technologies specializes in developing innovative solutions to restore vision for individuals with retinal diseases, positioning itself as a key player in medical technology advancements. Bionic Vision Technologies Pty. Ltd. , founded in 2010 and headquartered in Melbourne, Australia, focuses on developing advanced visual implants.

The company, led by CEO Ash Attia, has received a total funding of AUD 23. 5 mn across multiple rounds, with its most recent funding of AUD 1 mn in a Grant from the Department of Health and Ageing on February 16, 2021. Bionic Vision Technologies specializes in the development of the BVT Bionic Eye System, recognized as the world’s first suprachoroidal visual implant. This device aims to restore functional vision for individuals suffering from inherited retinal diseases by delivering visual information directly to the brain.

Initial human trials have shown its safety and efficacy, with plans to expand clinical trials to Australia, the USA, and Europe. Revenue generation for Bionic Vision Technologies is focused on the commercialization of the BVT Bionic Eye System through partnerships with specialized retinal clinics and hospitals. Pricing is determined through agreements with these healthcare providers, positioning the company to expand its revenue model as it moves forward with global clinical trials and regulatory approvals. Bionic Vision Technologies plans to utilize the recent AUD 1 mn Grant funding to finalize the development of sophisticated vision processing software.

This software will convert images from smart glasses into brain stimuli, enhancing the user’s visual perception. The company aims to expand its clinical trials in Australia, the USA, and Europe, with the goal of commercializing its Bionic Eye System following successful outcomes.